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Objectives
The efficacy of current hepatitis C virus (HCV) triple therapy, including a protease inhibitor, is
limited in HIV/HCV-coinfected patients with advanced liver fibrosis and nonresponse to previous
peginterferon-ribavirin. These patients have a low chance (only 30%) of achieving a sustained
virological response (SVR) during triple therapy and cannot wait for next-generation anti-HCV
drugs. In a pilot study, we investigated the efficacy of a lead-in therapy with silibinin before
triple therapy in difficult-to-treat patients.
Methods
Inclusion criteria were HIV/HCV coinfection with advanced liver fibrosis and documented failure
of previous peginterferon-ribavirin treatment. Intervention was lead-in therapy with intravenous
silibinin 20 mg/kg/day for 14 days. Subsequently, peginterferon-ribavirin combined with
telaprevir was initiated for 12 weeks, followed by peginterferon-ribavirin dual therapy until
week 48 after initiation of triple therapy. The outcome measurements were HCV RNA after
silibinin lead-in, at weeks 2, 4 and 12 of triple therapy, and SVR at week 24 after the end of
treatment.
Results
We examined six HIV/HCV-coinfected patients (four infected with genotype 1a). All had fibrosis
grade METAVIR ≥F3 and were on fully suppressive antiretroviral therapy. Mean HCV RNA
decline after silibinin therapy was 2.6 log10 IU/mL (range 2–3 log10 IU/mL). Five of the six
patients were virologically suppressed at weeks 2 and 4, and all six at week 12 of triple therapy.
One experienced a viral breakthrough thereafter. Four of five patients (80%) showed an SVR 24.
One patient had an SVR 12 but has not yet reached week 24.
Conclusions
A lead-in with silibinin before triple therapy is highly effective and increases the probability of
HCV treatment success in difficult-to-treat HIV/HCV-coinfected patients with advanced liver
fibrosis and previous failure of peginterferon-ribavirin.
Keywords: advanced liver fibrosis, hepatitis C virus, HIV/hepatitis C virus coinfection,
nonresponse, null response, silibinin.
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Introduction
Chronic hepatitis C virus (HCV) infection has overtaken
HIV type 1 infection as a cause of death in developed
countries [1]. The protease inhibitors telaprevir and
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boceprevir were approved in Switzerland at the end of
2011 as the first direct-acting anti-HCV drugs (DAAs) in
combination with pegylated interferon alpha-2a plus
ribavirin (peginterferon-ribavirin) triple therapy (TT)
for HCV-monoinfected and HCV/HIV-coinfected patients
with genotype 1. However, despite the availability of TT,
treating HCV infection remains challenging in difficult-
to-treat patients, such as HIV/HCV-coinfected patients
with advanced liver fibrosis and previous failure of
peginterferon-ribavirin therapy. These patients are at the
highest risk for HCV-related complications [2]. At the same
time, they have the lowest chance (around 30%) of achiev-
ing a sustained virological response (SVR) with TT, and they
are at the highest risk for on-treatment virological failure
[3]. As these patients cannot wait until the next generation
of anti-HCV drugs is available, new therapeutic options to
eradicate HCV and to prevent further progression and com-
plications of HCV infection are urgently needed [4].
A promising drug is silibinin, which targets different
steps in the HCV lifecycle [5]. A pilot study showed that
administration of 20 mg/kg intravenous silibinin signifi-
cantly reduced HCV RNA (reduction 3.02 mean ± standard
deviation 1.01 log10 IU/mL) in 20 HCV-monoinfected pati-
ents with previous null response to peginterferon-ribavirin
therapy [6].
Encouraged by these findings, we investigated the use
of intravenous silibinin followed by TT in HIV/HCV-
coinfected patients with advanced liver fibrosis and previ-
ous failure of peginterferon-ribavirin therapy. We used
intravenous silibinin as a lead-in therapy with the aim of
rapidly lowering HCV RNA before TT initiation, and thus
increasing the chance of treatment success. We report the
efficacy and tolerability of silibinin in six difficult-to-treat
coinfected patients as a proof of principle.
Methods
Objectives
The primary aim was to describe the efficacy and safety of
a 14-day lead-in of intravenous silibinin in HIV/HCV-
coinfected patients with advanced liver fibrosis who failed
on previous treatment with peginterferon-ribavirin. Our
secondary aim was to assess the viral response to silibinin
and the following TT, during and at the end of treatment.
Patient selection and previous responses to
HCV therapy
We treated six patients coinfected with HIV/HCV genotype
1 with a silibinin lead-in and subsequent TT. Patients were
selected based on a documented history of previous failure
of peginterferon-ribavirin, including null response (NR),
partial response (paR), relapse or viral breakthrough, and
documented advanced liver fibrosis. Virological responses
were defined as published elsewhere [7]. Advanced liver
fibrosis was defined as a METAVIR fibrosis score ≥ 3 in at
least one documented liver biopsy since diagnosis of HCV
infection.
Investigational product and mode of treatment
Intravenous silibinin is commercially available as Legalon®
SIL (Rottapharm Madaus, Cologne, Germany). In Austria,
Legalon® SIL is approved for treatment of chronically HCV-
infected patients with nonresponse to standard therapy with
peginterferon-ribavirin. In Switzerland, Legalon® is accepted
for compassionate use for the same indication. All patients
received lead-in therapy with intravenous silibinin at 20 mg/
kg/day once a day for 14 days. After a 14-day intravenous
silibinin lead-in treatment, patients started standard TT on
day 15, including telaprevir and peginterferon-ribavirin.
TT was continued for 12 weeks, followed by 36 weeks of
peginterferon-ribavirin.
Assessment of HCV RNA, drug resistance testing,
silibinin safety and tolerability, and antiretroviral
drug levels
A safety laboratory assessment was obtained on days 1, 8,
12 and 15 of silibinin lead-in, and during subsequent TT and
peginterferon-ribavirin therapy. Serum HCV RNA levels
were determined using Roche COBAS TaqMan v2.0
(Rotkreuz, Switzerland) (sensitivity range < 15 IU/mL). HCV
RNA was obtained 2 weeks before the first silibinin admin-
istration, on day 1 of silibinin lead-in, and also on days 8, 12
and 15 of silibinin lead-in (i.e. week 0 of TT). HCV viral load
was monitored during TT at weeks 2, 4 and 12, and during
peginterferon-ribavirin dual therapy at weeks 24 and 48
after initiation of TT. HCV drug resistance testing was
performed by Janssen Diagnostics (Raritan, NJ, USA) using
a population-based sequencing assay to determine HCV
NS3/4A sequence. The antiretroviral drug levels were meas-
ured at days 1 and 15 by liquid chromatography−tandem
mass spectrometry with automated online sample extrac-
tion. The tolerability of intravenous silibinin was deter-
mined by daily clinical assessment during the silibinin
treatment period.
Results
Patient characteristics
The six patients had a median age of 49 years (range 38–56
years) (Table 1). HCV transmission was via injecting drug
use (n = 4), via contaminated blood products (n = 1) and
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unknown (n = 1). All patients were on fully suppressive
antiretroviral therapy (ART) (i.e. < 20 HIV-1 RNA
copies/mL plasma) and had a median CD4 T-cell count
of 574 cells/μL (range 175–686 cells/μL). Genotype testing
revealed genotype 1a (n = 4), genotype 1b (n = 1) and
genotype 1e (n = 1). All patients had advanced liver fibrosis
with a METAVIR fibrosis score of ≥3, and a fibroscan
stiffness of ≥14 kPa. Patients had experienced a previous
NR (n = 3), a paR (n = 1), a viral breakthrough (n = 1) and a
relapse (n = 1) (Fig. 1a). The ART regimens consisted of
atazanavir/ritonavir (ATV/r), raltegravir (RGV), efavirenz
(EFV), tenofovir (TDF), emtricitabine (FTC), abacavir (ABC)
and lamivudine (3TC).
HCV and HIV-1 RNA during silibinin lead-in and HCV
triple therapy
During the 14 days of intravenous silibinin therapy, four of
the six patients experienced a 3 log10 IU/mL HCV RNA
decline, and two patients a 2 log10 IU/mL HCV RNA decline;
the mean HCV RNA decline was 2.6 log10 IU/mL (Fig. 1b).
After the silibinin lead-in therapy and initiation of TT,
five of the six patients reached an HCV RNA below the
limit of detection at week 2 of TT, and all six patients
did so at week 12 of TT (Fig. 1b). During the subsequent
peginterferon-ribavirin therapy, patient B, with the geno-
type 1e, had a viral breakthrough at week 32 after initia-
tion of TT. Drug resistance testing of the HCV NS3 protease
region from the failing patient revealed the I132V muta-
tion, which may be associated with resistance to telaprevir.
Four of five patients (80%) showed an SVR 24. One patient
has not yet reached week 24 after the end of treatment but
had an SVR at week 12 after the end of treatment.
Table 1 Baseline characteristics of six HIV/hepatitis C virus (HCV)-coinfected patients
Patient Age (years) Sex CD4 count (cells/μl) ART GT METAVIR Fibroscan (kPa) Preceding peginterferon-ribavirin
A 49 m 396 RGV 1a F3 35.8 Null response
ATV/r
TDF
B 48 f 520 RGV 1e F3 19.8 Null response
TDF/FTC
C 50 m 627 RGV 1a F3 18.4 Viral breakthrough
ATV/r
TDF
D 47 m 686 RGV 1b F3 NA Partial response
ABC/3TC
E 56 m 678 RGV 1a F3 14.3 Relapse
ATV/r
3TC
F 38 m 175 RGV 1a NA 24.6 Null response
EFV
TDF/FTC
ART, antiretroviral therapy; GT, genotype; NA, not available; RGV, raltegravir; ATV/r, atazanavir/ritonavir; EFV, efavirenz; TDF, tenofovir; FTC, emtricitabine;
3TC, lamivudine; m, male; f, female.
Fig. 1 Historical treatment response compared to our pilot study. (a)
Previous treatment failure in six HIV/hepatitis C virus (HCV)-coinfected
patients with pegylated interferon alpha-2a plus ribavirin dual therapy
(PR). The dotted line indicates the failing patient shown in panel b. (b)
HCV RNA viral load in the same six patients during lead-in therapy with
intravenous silibinin for 14 days followed by initiation of triple therapy
on day 15 (i.e. week 0) for 12 weeks, and peginterferon-ribavirin dual
therapy for 36 weeks. The black arrows indicate the different treatment
durations with PR in the six patients. bld, below the level of detection;
EOTR, end of treatment response; SVR 24, sustained virological
response 24 weeks after the end of treatment; PR, pegylated interferon
alpha-2a plus ribavirin.
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Adverse events associated with intravenous silibinin
Intravenous silibinin was well tolerated without any
serious adverse events. The most common adverse event
was a sensation of heat in three of six patients that receded
spontaneously.
Antiretroviral drug levels
Concentrations of antiretroviral drugs (i.e. ATV, RGV and
EFV) were not significantly influenced by silibinin lead-in
therapy. All results for trough levels were within the stand-
ard reference values (ATV: 0.7–1.0 mg/L; reference value
0.86 ± 0.84; RGV: 0.07–0.78; reference value 0.04−1.00;
EVF: 2.8–3.4; reference value 1.7 ± 1.0) [8].
Discussion
In this pilot study, a silibinin lead-in followed by TT,
including the protease inhibitor telaprevir, led to an SVR 24
in four of five (80%) difficult-to-treat HIV/HCV-coinfected
patients with previous failure of peginterferon-ribavirin
treatment. We observed a rapid HCV RNA decline during
silibinin treatment, which decreased below the limit of
detection after 2 weeks of TT in five of the six patients.
An SVR 24 rate of 80% is high given the current data on
treatment success of TT in HCV treatment-experienced
patients with advanced liver fibrosis. The REALIZE
(telaprevir for retreatment of HCV-infection) trial reported
an SVR of only 29% in 72 HCV-monoinfected patients
with previous NR to peginterferon-ribavirin, retreated with
telaprevir-based TT [9]. On-treatment virological failure in
the REALIZE trial occurred in 18% of patients overall (i.e. in
52% of those with prior NR, in 19% of those with paR and in
1% of relapsers) [3]. The French early-access programme
Agence Nationale de Recherche sur le SIDA (ANRS) C020-
CUPIC enrolled 674 monoinfected cirrhotic patients with
HCV genotype 1 and reported SVR 12 rates of 40% in the
telaprevir group and 41% in the boceprevir group. In a
subgroup analysis, patients with previous paR and NR had
substantially lower treatment responses, with SVR rates at
week 12 of 32% and 29% in the telaprevir group, and of 40%
and 11% in the boceprevir group, respectively [10]. Recently,
a European cohort study of HIV/HCV-coinfected patients
reported real-life on-treatment data: in the ANRS CO13-
HEPAVIH cohort/ESCMID European Study, 69% of 65 par-
ticipants were previous nonresponders, 80% were infected
with HCV genotype 1a, and the mean transient elastometry
was 19.3 kPa [11]. This study population was similar to ours,
but the virological response at week 48 was only 17% in the
telaprevir group and 33% in the boceprevir group. The lower
response rate in the telaprevir group was explained by the
higher fraction of patients with the unfavourable genotype
1a compared with the boceprevir group. In summary, the
treatment responses in our pilot study were substantially
higher than those of similar patient groups reported in the
literature. Of note, the SVR would also be high (75%) if the
individual with a relapse after previous treatment with
peginterferon-ribavirin were excluded.
We hypothesize that the high on-treatment and the high
SVR rate in our pilot study is related to the lead-in therapy
with silibinin. The 2–3 log10 IU/mL viral RNA decline during
the silibinin lead-in and thus the lower viral load when
starting TT might have been key for subsequent treatment
success [12,13]. A lower baseline viral load led to more rapid
viral clearance and presumably prevented the development
of resistance against telaprevir. In patients with prior
peginterferon-ribavirin failure, the cornerstone of TT is the
protease inhibitor, as peginterferon-ribavirin turned out to
be ‘weak’ partners with increased risk for the emergence of
HCV resistance variants and viral breakthrough [14]. That
the ongoing viral replication is associated with the devel-
opment of HCV resistance mutations [15] is also supported
by the results of our analyses of the HCV NS3 protease
region, which revealed the I132V mutation in the woman
with a viral breakthrough harbouring the genotype 1e. This
patient had a slower HCV RNA decline after treatment
initiation compared with the viral slopes of the other five
patients. She had an ongoing low-level viraemia until
virological suppression was achieved at week 12, and she
subsequently had a viral breakthrough at week 32.
Although new HCV therapeutics were recently approved
by the US Food and Drug Administration, or will be
approved soon, we are convinced that silibinin will be of
value for selected difficult-to-treat patients. First, informa-
tion about treatment outcome with newer DAAs in cirrhotic
HIV/HCV-coinfected patients with previous NR is limited.
Of note, for sofosbuvir there are no data from phase 3 trials
for treatment-experienced patients with genotype 1.
Furthermore, phase 3 trials reported significantly lower
SVR rates in therapy-experienced patients with prior
NR, paR or viral breakthrough, compared with therapy-
naive patients [16,17]. Secondly, interferon-free oral
drug combinations might soon become standard of care,
but, in many trials with HIV/HCV-coinfected patients,
new DAAs, including simeprevir, faldaprevir, sofosbuvir
and daclatasvir, were still combined with peginterferon-
ribavirin, especially for genotype 1 [18,19]. Thirdly, the
extremely high costs of DAAs may limit access to therapy,
and from a global perspective the newer DAAs are not
available in many countries. In contrast, silibinin is com-
mercially available and would be accepted for compassion-
ate use in most countries. The very recently published
British HIV Association guideline 2013 recommends
that, for patients with genotype 1 and a current clinical
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need for treatment, the standard of care should be a TT
with peginterferon-ribavirin combined with either
telaprevir or boceprevir [20]. Thus, the add-on of silibinin
to peginterferon-ribavirin in combination with first-
generation protease inhibitors may be a valuable and
affordable alternative for treating patients with previous
NR or paR, or patients with advanced fibrosis, and may
increase the probability of achieving an SVR.
This proof of principle study with a surprisingly high
SVR rate of 80% has limitations. First, the actual contri-
bution of the silibinin lead-in to the SVR rate is difficult to
estimate, as our trial was not randomized and did not
include a placebo group without silibinin. Secondly, the
number of patients was small, and thus the SVR rate must
be confirmed in a larger trial. However, the strength of our
study is the real-life setting, including patients who
urgently need new treatment strategies.
In conclusion, our pilot study demonstrates as a proof of
principle that a 14-day lead-in with intravenous silibinin
followed by TT is effective in difficult-to-treat HIV/HCV-
coinfected patients. This translates into HCV treatment
success in these patients with advanced liver fibrosis and
previous failure of peginterferon-ribavirin.
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